MedDataX Logo

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

NCT ID: NCT01994681

Last Updated: 2013-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven Pancreatic cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pancreatic Cancer

No interventions assigned to this group

Healthy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 years old
* Pancreatic cancer positive biopsy
* Before any treatment
* Signed Informed Patient Consent


* Healthy patients
* No history of Pancreatic cancer
* Signed Informed Patient Consent

Exclusion Criteria

* Age under 18 years old
* Neoadjovant treatment
* Post surgery for Pancreatic cancer
* A history of any other cancer type, except skin cancer that is not melanoma

Healthy Group


* History of Pancreatic cancer
* Pancreatic cancer background in the family
* A history of any other cancer type, except skin cancer that is not melanoma
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Spectrosense Ltd.

INDUSTRY

Sponsor Role collaborator

Rauscher, Gregory E., M.D. PA

INDIV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Gutierrez, MD

Role: PRINCIPAL_INVESTIGATOR

Hackensack Meridian Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kevin Barga

Role: CONTACT

Phone: (551)996-8017

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

00004108

Identifier Type: -

Identifier Source: org_study_id